Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fesoterodine - Pfizer

Drug Profile

Fesoterodine - Pfizer

Alternative Names: Fesosterodine; Fesoterodine fumarate; PF-00695838; PF-695838; SPM 007; SPM 907; Toviaz

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schwarz Pharma
  • Developer Pfizer
  • Class Antispasmodics; Benzhydryl compounds; Esters; Propionic acids; Small molecules; Urologics
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder
  • No development reported Stress incontinence

Most Recent Events

  • 28 Aug 2022 No recent reports of development identified for phase-I development in Overactive bladder(In volunteers) in Belgium (PO, Controlled release)
  • 04 Jan 2021 Pfizer completes a a phase I trial (In volunteers) in Belgium (NCT04452838)
  • 12 Nov 2020 Pfizer completes a phase I Bioequivalence trial in Healthy volunteers in Belgium (PO) (NCT04478357)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top